Here are the editors' top picks for the week ended Oct. 6.
Trump tax plan could unlock pharma's record offshore cash pile
Big Pharma could have a chance to bring record-high foreign cash holdings back to the U.S. at a significant discount under the Trump administration's tax reform proposal.
US faces dire drug shortages if Puerto Rico plants not restored, FDA chief warns
If medical product facilities in hurricane-stricken Puerto Rico are not restored soon, the U.S. could face shortages of critical therapies, the head of the U.S. Food and Drug Administration warned lawmakers.
FDA takes action to stem 'public health concern' of high-priced complex drugs
When Americans cannot afford their medicines, "that's a public health concern" the FDA plans to do something about, even though it lacks the regulatory authority to rein in prices, the agency's commissioner said.
Virginia spending more than $500M on unneeded, low-cost lab tests, study finds
Hospitals may be racking up hundreds of millions of dollars in unnecessary, low-cost services on patients in Virginia alone, according to a study in the journal Health Affairs.
Express Scripts warns of rising per-person drug expenditure in US
The number of people in the U.S. with more than $50,000 in 2016 in prescription drug costs has gone up 35% in two years, according to a new report from pharmacy benefit manager Express Scripts Holding Co.
China FDA's Sovaldi nod could usher in more fast track approvals
Accelerated approvals for imported drugs is now a reality in China, and industry experts believe foreign manufacturers are pitching more of them in order to access the world's second largest pharmaceutical market.
Capitol Checkup: Gottlieb's busy month ends with speculation of HHS top job
FDA Commissioner Scott Gottlieb's busy September of laying the groundwork for change ended with speculation he could leave the agency before those actions are implemented to be the next head of Health and Human Services.
Teva's flagship product feels sooner-than-expected heat with Mylan approval
Mylan NV's approval to launch the first 40-milligram generic of Teva Pharmaceutical Industries Ltd.'s Copaxone in the U.S. has analysts predicting a bleaker future for the already struggling Israeli drugmaker.
FDA chief cautions lawmakers not to grant broad access to experimental drugs
Congress needs to ensure it is not making the patient eligibility criteria too broad in legislation that seeks to expand access to experimental treatments, the head of the U.S. FDA cautioned.